Tempest director granted 1,230 stock options at $2.94

Tempest Therapeutics director receives stock option grant.

Rhea-AI Filing Summary

Tempest Therapeutics director receives stock option grant. Director Michael Raab was granted a stock option to purchase 1,230 shares of Tempest Therapeutics, Inc. common stock at an exercise price of $2.94 per share on January 27, 2026.

The option vests in full on the earlier of January 27, 2027 or the date of the company’s 2026 annual stockholder meeting, contingent on his continuous service through that date. Following this grant, he beneficially owns 1,230 derivative securities directly, with the option expiring on January 26, 2036.

Insider Trade Summary

Grant/Award: 1,230 shares

Grant/Award 1 txn

Insider RAAB MICHAEL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	1,230	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 1,230 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tempest Therapeutics (TPST) report in this Form 4 filing?

Tempest Therapeutics reported a stock option grant to director Michael Raab. He received options for 1,230 shares of common stock at an exercise price of $2.94 per share, dated January 27, 2026, recorded as directly owned derivative securities after the transaction.

How many Tempest Therapeutics shares are covered by Michael Raab’s new option?

Michael Raab’s new stock option covers 1,230 shares of Tempest Therapeutics common stock. These shares are underlying a single option award reported as a derivative security, with 1,230 derivative securities beneficially owned directly following the transaction recorded on January 27, 2026.

What is the exercise price and term of Michael Raab’s Tempest Therapeutics option?

The stock option has an exercise price of $2.94 per share and expires on January 26, 2036. It is reported as a derivative security, giving the director the right to buy 1,230 shares of Tempest Therapeutics common stock during that option term.

When does Michael Raab’s Tempest Therapeutics stock option vest?

The option will vest in full on the earlier of January 27, 2027 or the date of Tempest Therapeutics’ 2026 annual stockholder meeting. Vesting is conditioned on Michael Raab’s continuous service with the company through the applicable vesting date specified in the award terms.

What is Michael Raab’s ownership status after this Tempest Therapeutics option grant?

After the grant, Michael Raab beneficially owns 1,230 derivative securities directly, representing the reported stock option. The Form 4 indicates these are held in direct ownership form, reflecting the entire number of options received in the January 27, 2026 award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/28/2026 - 04:30 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAAB MICHAEL

(Last) (First) (Middle)

C/O TEMPEST THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 400

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tempest Therapeutics, Inc. [ TPST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.94	01/27/2026		A		1,230		(1)	01/26/2036	Common Stock	1,230	$0	1,230	D

Explanation of Responses:

1. The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Nicholas Maestas, Attorney-in-Fact	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.